Johnson & Johnson (JNJ) operating KPIs
JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3043% above fair value
$273.20−2.00 (-0.73%)
Close on Oct 30, 2026Market cap $658.38BP/E 31.7Yield 1.88%
Johnson & Johnson vision Franchise — Worldwide sales ($M) ($M)
Form 10-Q / 10-K Segment Note & Form 8-K EX-99.2 Segment Sales Schedule
Latest, Q3 2026
1,461
Period ended Sep 30, 2026
Change on a year earlier
+4.4%
1,400 in Q3 2025
History
39 quarters
Since Q1 2017
Sources
31
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Vision Franchise — Worldwide sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q3 2026 | Sep 30, 2026 | 1,461 | +4.4% | Form 10-Q (filed 2026-10-21) ↗ |
| Q2 2026 | Jun 28, 2026 | 1,451 | +6.0% | Form 10-Q (filed 2026-07-23) ↗ |
| Q1 2026 | Mar 29, 2026 | 1,365 | +6.7% | Form 10-Q (filed 2026-04-22) ↗ |
| Q4 2025 | Dec 28, 2025 | 1,420 | +9.0% | Form 10-K (filed 2026-02-11) ↗ |
| Q3 2025 | Sep 28, 2025 | 1,400 | +7.7% | Form 10-Q (filed 2026-10-21) ↗ |
| Q2 2025 | Jun 29, 2025 | 1,369 | +6.5% | Form 10-Q (filed 2026-07-23) ↗ |
| Q1 2025 | Mar 30, 2025 | 1,279 | +1.7% | Form 10-Q (filed 2026-04-22) ↗ |
| Q4 2024 | Dec 29, 2024 | 1,303 | +7.9% | Form 10-K (filed 2026-02-11) ↗ |
| Q3 2024 | Sep 29, 2024 | 1,300 | +3.5% | Form 10-Q (filed 2025-10-22) ↗ |
| Q2 2024 | Jun 30, 2024 | 1,285 | -1.8% | Form 10-Q (filed 2025-07-24) ↗ |
| Q1 2024 | Mar 31, 2024 | 1,258 | -3.2% | Form 10-Q (filed 2025-04-23) ↗ |
| Q4 2023 | Dec 31, 2023 | 1,208 | +5.5% | Form 10-K (filed 2026-02-11) ↗ |
| Q3 2023 | Oct 1, 2023 | 1,256 | +4.1% | Form 10-Q (filed 2024-10-23) ↗ |
| Q2 2023 | Jul 2, 2023 | 1,308 | +5.4% | Form 10-Q (filed 2024-07-25) ↗ |
| Q1 2023 | Apr 2, 2023 | 1,300 | +3.4% | Form 10-Q (filed 2024-05-01) ↗ |
| Q4 2022 | Jan 1, 2023 | 1,145 | -2.2% | Form 10-K (filed 2025-02-13) ↗ |
| Q3 2022 | Oct 2, 2022 | 1,206 | +1.4% | Form 10-Q (filed 2023-10-27) ↗ |
| Q2 2022 | Jul 3, 2022 | 1,241 | +4.9% | Form 10-Q (filed 2023-07-31) ↗ |
| Q1 2022 | Apr 3, 2022 | 1,257 | +9.8% | Form 10-Q (filed 2023-04-28) ↗ |
| Q4 2021 | Jan 2, 2022 | 1,171 | +8.8% | Form 10-K (filed 2024-02-16) ↗ |
| Q3 2021 | Oct 3, 2021 | 1,189 | +10.0% | Form 10-Q (filed 2022-10-27) ↗ |
| Q2 2021 | Jul 4, 2021 | 1,183 | +70.2% | Form 10-Q (filed 2022-07-29) ↗ |
| Q1 2021 | Apr 4, 2021 | 1,145 | +7.3% | Form 10-Q (filed 2022-04-29) ↗ |
| Q4 2020 | Jan 3, 2021 | 1,076 | -5.7% | Form 10-K (filed 2023-02-16) ↗ |
| Q3 2020 | Sep 27, 2020 | 1,081 | -9.4% | Form 10-Q (filed 2021-10-29) ↗ |
| Q2 2020 | Jun 28, 2020 | 695 | -40.1% | Form 10-Q (filed 2021-07-29) ↗ |
| Q1 2020 | Mar 29, 2020 | 1,067 | -5.5% | Form 10-Q (filed 2021-04-30) ↗ |
| Q4 2019 | Dec 29, 2019 | 1,141 | +0.7% | Form 10-K (filed 2022-02-17) ↗ |
| Q3 2019 | Sep 29, 2019 | 1,193 | +5.4% | Form 10-Q (filed 2020-10-23) ↗ |
| Q2 2019 | Jun 30, 2019 | 1,161 | -1.0% | Form 10-Q (filed 2020-07-24) ↗ |
| Q1 2019 | Mar 31, 2019 | 1,129 | +1.3% | Form 10-Q (filed 2019-05-01) ↗ |
| Q4 2018 | Dec 30, 2018 | 1,133 | +1.3% | Form 10-K (filed 2021-02-22) ↗ |
| Q3 2018 | Sep 30, 2018 | 1,132 | +3.8% | Form 10-Q (filed 2018-10-31) ↗ |
| Q2 2018 | Jul 1, 2018 | 1,173 | +11.2% | Form 10-Q (filed 2018-08-02) ↗ |
| Q1 2018 | Apr 1, 2018 | 1,115 | +39.7% | Form 10-Q (filed 2019-05-01) ↗ |
| Q4 2017 | Dec 31, 2017 | 1,119 | – | Form 10-K (filed 2019-02-20) ↗ |
| Q3 2017 | Oct 1, 2017 | 1,091 | – | Form 10-Q (filed 2018-10-31) ↗ |
| Q2 2017 | Jul 2, 2017 | 1,055 | – | Form 10-Q (filed 2018-08-02) ↗ |
| Q1 2017 | Apr 2, 2017 | 798 | – | Form 10-Q (filed 2018-05-01) ↗ |
Breakdown
What makes up vision franchise — worldwide sales ($m)
- Vision Franchise — U.S. sales ($M)596 · Q3 2026
- Vision Franchise — International sales ($M)865 · Q3 2026
- Vision Franchise — Worldwide reported growth YoY (%)4.4% · Q3 2026
- Vision Franchise — Worldwide operational (constant-currency) growth YoY (%)5.1% · Q3 2026
- Contact Lenses / Other (ACUVUE) — Worldwide sales ($M)1,053 · Q3 2026
- Surgical Vision (intraocular lenses / cataract) — Worldwide sales ($M)408 · Q3 2026
Cite this data
StockData. (2026). Johnson & Johnson Vision Franchise — Worldwide sales ($M) ($M), quarterly Q1 2017–Q3 2026 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/mt_vision
See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.